单克隆抗体治疗免疫性周围神经病进展  

Monoclonal antibodies for diseases of the peripheral nervous system

作　　者：孙广锋[1] 余建华[1] 

机构地区：[1]武警湖北总队医院神经内二科

出　　处：《免疫学杂志》2011年第4期361-364,共4页Immunological Journal

摘　　要：免疫性周围神经病如慢性炎症性脱髓鞘性多发性神经病(CIDP)、多病灶运动神经病(MMN)等常规方法治疗疗效有时较差和毒性较大。目前几种单克隆抗体(MAbs)已经试用于免疫性周围神经病的治疗。小范围研究或在单个病例,以建立未来的方向周围神经系统疾病治疗的未来方向。利妥昔单抗,是治疗免疫性神经病应用最广泛和最有前景的MAb,阿仑单抗和贝伐单抗等也试用于治疗各种免疫异常的神经病变。对有些难治性周围神经病,单克隆抗体是一种新的安全有效的治疗方法。Conventional treatment options,corticosteroids,intravenous immunoglobulin,or plasma exchange,often fail to treat dysimmune neuropathies,such as chronic inflammatory demyelinating polyneuropathy,multifocal motor neuropathy,and monoclonal gammopathy.Currently,several monoclonal antibodies（MAbs） have been tested in the therapy for diseases of the peripheral nervous system（PNS）.Rituximab,is the most widely used and a promising MAb for the treatment of dysimmune neuropathies.The efficacy of alemtuzumab and bevacizumab on treating various forms of dysimmune neuropathies is currently under investigation,especially for disorders that are resistant to conventional treatment options.

关 键 词：单克隆抗体 免疫性周围神经病 分子靶向治疗 

分 类 号：R744[医药卫生—神经病学与精神病学]